Comment: Celgene pipeline cancer drug could raise eyebrows in Bristol-Myers deal
Celgene has the rights to a liver cancer drug in the development pipeline that would compete with Bristol-Myers Squibb’s Opdivo, potentially creating an antitrust problem given signs of growing FTC resistance...To view the full article, register now.
Already a subscriber? Click here to view full article